KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Average (2016 - 2025)

Historic Equity Average for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $20.6 billion.

  • Gilead Sciences' Equity Average rose 1264.66% to $20.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 billion, marking a year-over-year increase of 1264.66%. This contributed to the annual value of $21.0 billion for FY2024, which is 427.45% down from last year.
  • Latest data reveals that Gilead Sciences reported Equity Average of $20.6 billion as of Q3 2025, which was up 1264.66% from $19.4 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Equity Average ranged from a high of $22.5 billion in Q4 2023 and a low of $17.8 billion during Q2 2024
  • Moreover, its 5-year median value for Equity Average was $20.5 billion (2022), whereas its average is $20.1 billion.
  • The largest annual percentage gain for Gilead Sciences' Equity Average in the last 5 years was 1917.24% (2021), contrasted with its biggest fall of 1705.15% (2021).
  • Over the past 5 years, Gilead Sciences' Equity Average (Quarter) stood at $21.3 billion in 2021, then fell by 0.63% to $21.1 billion in 2022, then rose by 6.45% to $22.5 billion in 2023, then dropped by 16.16% to $18.9 billion in 2024, then rose by 9.26% to $20.6 billion in 2025.
  • Its Equity Average stands at $20.6 billion for Q3 2025, versus $19.4 billion for Q2 2025 and $19.2 billion for Q1 2025.